317319-09-8

Basic information

• Product Name: Acetic acid, [4-(acetyloxy)-2-methylphenoxy]-, methyl ester
• CAS NO: 317319-09-8
• Molecular Formula: C12H14O5
• Molecular Weight: 238.24
• Mol File: 317319-09-8.mol
• Article Data: 12

Chemical Properties

• CAS DataBase Reference: Acetic acid, [4-(acetyloxy)-2-methylphenoxy]-, methyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: Acetic acid, [4-(acetyloxy)-2-methylphenoxy]-, methyl ester(317319-09-8)
• EPA Substance Registry System: Acetic acid, [4-(acetyloxy)-2-methylphenoxy]-, methyl ester(317319-09-8)

Safety Data

• Hazardous Substances Data: 317319-09-8(Hazardous Substances Data)

Upstream product

• 95-48-7 ortho-cresol 
• 2989-17-5 methyl 2-methylphenoxy acetate 
• 876-02-8 4-hydroxy-3-methylphenyl methyl ketone 
• 166953-80-6 (4-acetyl-2-methylphenoxy)acetic acid methyl ester 

Downstream Products

• 317319-10-1 methyl (4-hydroxy-2-methylphenoxy)acetate 
• 870289-01-3 [4-(5-bromo-4'-methoxy-biphenyl-3-ylmethoxy)-2-methyl-phenoxy]-acetic acid methyl ester 
• 869015-14-5 (4-[3,3-bis-(4-iodophenyl)allyloxy]-2-methylphenoxy)acetic acid methyl ester 
• 869014-75-5 (4-{3,3-bis-[4-(3-pyrrolidin-1-yl-prop-1-ynyl)phenyl]allyloxy}-2-methylphenoxy)acetic acid 
• 869015-29-2 (4-{3,3-bis-[4-(3-pyrrolidin-1-yl-prop-1-ynyl)phenyl]allyloxy}-2-methylphenoxy)acetic acid methyl ester 
• 317318-84-6 GW 0742 

Relevant articles and documents

Discovery of first-in-class thiazole-based dual FFA1/PPARδ agonists as potential anti-diabetic agents

The free fatty acid receptor 1 (FFA1 or GPR40) and peroxisome proliferator-activated receptor δ (PPARδ) have attracted a lot of attention due to their role in promoting insulin secretion and sensibility, respectively, which are two major features of diabetes. Therefore, the dual FFA1/PPARδ agonists would increase insulin secretion and sensibility by FFA1 and PPARδ activation. In this study, we hybrid FFA1 agonist AM-4668 with PPARδ agonist GW501516, leading to the identification of orally bioavailable dual agonist 32, which revealed high selectivity over other PPARs. Moreover, compound 32 exhibited good pharmacokinetic profiles with high plasma concentration, sustained half-life and low clearance in vivo. During the hypoglycemic test, a dual agonist 32 enhanced the tolerance of ob/ob mice for glucose loading in a dose-dependent manner. Our results suggest that dual FFA1/PPARδ agonist could be a valuable therapy for type 2 diabetes.

Synthesis and biological evaluation of phenoxyacetic acid derivatives as novel free fatty acid receptor 1 agonists

Free fatty acid receptor 1 (FFA1) is a new potential drug target for the treatment of type 2 diabetes because of its role in amplifying glucose-stimulated insulin secretion in pancreatic β-cell. In the present studies, we identified phenoxyacetic acid derivative (18b) as a potent FFA1 agonist (EC50 = 62.3 nM) based on the structure of phenylpropanoic acid derivative 4p. Moreover, compound 18b could significantly improve oral glucose tolerance in ICR mice and dose-dependently reduced glucose levels in type 2 diabetic C57BL/6 mice without observation of hypoglycemic side effect. Additionally, compound 18b exhibited acceptable PK profiles. In summary, compound 18b with ideal PK profiles exhibited good activity in vitro and in vivo, and might be a promising drug candidate for the treatment of diabetes mellitus.

PROCESS FOR PREPARING PHENOXY ACETIC ACID DERIVATIVES

The preparation of an intermediate, a process for the preparation thereof and the process of preparing [4-[3,3-Bis-(4-bromo-phenyl)-allyloxy]-2-methyl-phenoxy]-acetic acid using this intermediate are described.